EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Evaluation of Nectin-4 and Trop-2: Implications for Patient Outcomes and Therapy in Penile Cancer

Jan Niklas Mink, Markus Eckstein, Oybek Khalmurzaev, Alexey Pryalukhin, Carol Geppert, Stefan Lohse, Kristof Bende, João Lobo, Rui Henrique, Hagen Loertzer, Joachim Steffens, Carmen Jerónimo und 7 weitere

Modern Pathology · 2025

DOI: 10.1016/j.modpat.2025.100781 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Modern Pathology, 2025. Verfasst von Jan Niklas Mink und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology and Paediatric Urology, Saarland University, Homburg, Germany. Electronic address: jan.mink@uks.eu. Hauptthemen laut MEDLINE: Cell Adhesion Molecules, Penile Neoplasms, Antigens, Neoplasm, Biomarkers, Tumor. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metastatic penile cancer (PC) continues to have a poor prognosis because of inadequate treatment options. Enfortumab vedotin and sacituzumab govitecan are antibody-drug conjugates (ADCs) that have significantly improved the prognosis of several other tumor types and are, therefore, promising candidates for the successful treatment of metastatic PC. We examined the expression of ADC targets Nectin-4 and Trop-2 in an international multicenter cohort of 203 PC patients both in the primary tumor and in metastases. In addition, we evaluated their prognostic values. Either intermediate or high Nectin-4 membrane expression was found in 28.0% of primary tumors and 18.8% of metastases. The expression in primary tumor decreased significantly with increasing T stage (P ≤ .001). It did not correlate with human papillomavirus status (P = .307) and was not associated with metastasis-free survival, cancer-specific survival, or overall survival. Nectin-4 expression levels at the tumor front and in metastases were significantly associated with each other (P = .005). Trop-2 was detected on the membrane of almost all samples with intermediate or high expression (primary tumor, 98.1%; metastasis, 100%). It was not associated with metastasis-free survival, cancer-specific survival, or overall survival. The expression at tumor front was significantly increased in human papillomavirus-positive tumors (P = .005). Neither Nectin-4 nor Trop-2 was found to be of prognostic value in PC. Enfortumab vedotin therapy seems promising for selected patients with high Nectin-4 expression, which should be confirmed in PC metastases before treatment is considered. Trop-2 is highly expressed in almost all PCs, and therefore, it is a very interesting potential target for sacituzumab govitecan therapy. Both ADCs warrant investigation in clinical trials focusing on PC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cell Adhesion MoleculesPenile NeoplasmsAntigens, NeoplasmBiomarkers, TumorHumansMaleMiddle AgedAgedAntibodies, Monoclonal, HumanizedAdultAged, 80 and overImmunoconjugatesAntibodies, MonoclonalPrognosisTreatment OutcomeNectinsCamptothecin

Stichwörter der Autor:innen

Nectin-4Trop-2antibody-drug conjugateimmunohistochemistrypenile squamous cell carcinoma

Substanzen

Cell Adhesion MoleculesNECTIN4 protein, humanAntigens, NeoplasmTACSTD2 protein, humanBiomarkers, TumorAntibodies, Monoclonal, HumanizedImmunoconjugatesAntibodies, Monoclonalenfortumab vedotinsacituzumab govitecan

Autor:innen und Institutionen

  • Department of Urology and Paediatric Urology, Saarland University, Homburg, Germany. Electronic address: jan.mink@uks.eu.
  • Institute of Pathology, University Erlangen-Nuremberg, Erlangen, Germany.
  • Department of Urology and Paediatric Urology, Saarland University, Homburg, Germany; Department of Urology, Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" оf the Ministry…
  • Institute of Pathology, Saarland University, Homburg, Germany.
  • Institute of Virology, Saarland University, Homburg, Germany.
  • Department of Pathology and Cancer Biology and Epigenetics Group, Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (P.CCC), Porto, Portugal; Department of Pathology and…

Zitieren

APA

Mink, J. N., Eckstein, M., Khalmurzaev, O., Pryalukhin, A., Geppert, C., Lohse, S., Bende, K., Lobo, J., Henrique, R., Loertzer, H., Steffens, J., Jerónimo, C., Wunderlich, H., Heinzelbecker, J., Bohle, R. M., Stöckle, M., Matveev, V., Hartmann, A., & Junker, K. (2025). Evaluation of Nectin-4 and Trop-2: Implications for Patient Outcomes and Therapy in Penile Cancer. Modern Pathology. https://doi.org/10.1016/j.modpat.2025.100781

Vancouver

Mink JN, Eckstein M, Khalmurzaev O, Pryalukhin A, Geppert C, Lohse S, et al. Evaluation of Nectin-4 and Trop-2: Implications for Patient Outcomes and Therapy in Penile Cancer. Modern Pathology. 2025. doi:10.1016/j.modpat.2025.100781

BibTeX
@article{Mink2025,
  author = {Mink, Jan Niklas and Eckstein, Markus and Khalmurzaev, Oybek and Pryalukhin, Alexey and Geppert, Carol and Lohse, Stefan and Bende, Kristof and Lobo, João and Henrique, Rui and Loertzer, Hagen and Steffens, Joachim and Jerónimo, Carmen and Wunderlich, Heiko and Heinzelbecker, Julia and Bohle, Rainer M and Stöckle, Michael and Matveev, Vsevolod and Hartmann, Arndt and Junker, Kerstin},
  title = {Evaluation of Nectin-4 and Trop-2: Implications for Patient Outcomes and Therapy in Penile Cancer},
  journal = {Modern Pathology},
  year = {2025},
  doi = {10.1016/j.modpat.2025.100781}
}
Kostenlos starten →